公开(公告)号：US20040235134A1

公开(公告)日：2004-11-25

申请号：US10788232

申请日：2004-02-26

Inventor： Bernardus Petrus Hubertus Peeters ,  Olav Sven de Leeuw ,  Guus Koch ,  Arnoud Leonard Josef Gielkens

IPC: C12N009/10 ,  C12N007/01 ,  C12N015/86

CPC classification number: C07K14/005 ,  A61K2039/51 ,  C12N15/86 ,  C12N2760/18122 ,  C12N2760/18143

Abstract: The invention relates to a process for generating infectious Newcastle disease virus (NDV) entirely from cloned full-length cDNA and to the use of vaccines and diagnostic assays generated with and derived from the process. The process offers the possibility to modify the NDV genome by means of genetic modification and allows for the introduction of mutations, deletions and/or insertions. The process can be used to modify the virulence of NDV, thus generating new attenuated live vaccines with enhanced properties. The process can be used to modify the antigenic make-up of NDV, to allow the generation of live NDV marker vaccines that can be serologically distinguished from NDV field strains.

Abstract translation: 本发明涉及一种完全由克隆的全长cDNA产生感染性新城疫病毒（NDV）的方法，以及使用由该方法产生和衍生的疫苗和诊断测定法。 该过程提供了通过遗传修饰来修饰NDV基因组并允许引入突变，缺失和/或插入的可能性。 该过程可用于修饰NDV的毒力，从而产生具有增强性质的新的减毒活疫苗。 该过程可用于修饰NDV的抗原构成，以产生可与NDV野毒株血清学区别的活NDV标记疫苗。

公开(公告)号：US20040180422A1

公开(公告)日：2004-09-16

申请号：US10723981

申请日：2003-11-26

Applicant: DYAX CORP.

Inventor： Rene Hoet ,  Robert Charles Ladner ,  Nicolas Frans

IPC: C12N005/02 ,  C12N005/00 ,  C12N007/01 ,  C12N007/00 ,  C07H021/04 ,  C12Q001/70

CPC classification number: C40B40/02 ,  C12N7/00 ,  C12N15/1037 ,  C12N15/86 ,  C12N2795/00022 ,  C12N2795/00043 ,  C12N2830/002 ,  C12N2830/38 ,  C12N2830/55

Abstract: Disclosed are methods and compositions useful, e.g., for controlling the valency of display proteins during display library screenings and selections. In one embodiment, they are applicable to phage and phage libraries that are based on bacteriophage, e.g., filamentous bacteriophage.

Abstract translation: 公开了可用于例如显示库筛选和显示库筛选期间显示蛋白质的价态的方法和组合物。 在一个实施方案中，它们可应用于基于噬菌体的噬菌体和噬菌体文库，例如丝状噬菌体。

公开(公告)号：US20040176583A1

公开(公告)日：2004-09-09

申请号：US10781599

申请日：2004-02-18

Inventor： Hiroaki Okamoto ,  Tsutomu Nishizawa

IPC: C12Q001/70 ,  C07H021/04 ,  A61K039/21 ,  C12N007/01 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C07K017/00 ,  C07K014/00 ,  C12N015/00 ,  C12P021/04 ,  C12N015/74 ,  C12Q001/68 ,  C12N007/00 ,  C07K001/00

CPC classification number: C12Q1/707 ,  A61K39/00 ,  A61K2039/505 ,  C07K14/005 ,  C12N2750/10022

Abstract: By isolating a so far unknown novel hepatitis virus and determining the gene sequence thereof, genes, polynucleotides, polypeptides, methods for isolating virus particles, virus particles, and antiviral antibodies, which can be used for diagnosis and treatment, as well as methods for detecting viruses are provided. Disclosed is a non-B, non-C, non-G hepatitis virus gene having a nucleotide sequence from which a sequence having a length of from about 3500 nucleotides to about 4000 nucleotides can be amplified by PCR utilizing an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 57 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 60 as primers, or PCR utilizing an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 57 and an oligonucleotide having the nucleotide sequence shown in SEQ ID NO: 61 as primers. Based on the nucleotide sequence of the gene, polypeptides etc. are provided.

Abstract translation: 通过分离迄今为止未知的新型肝炎病毒并确定其基因序列，可用于诊断和治疗的基因，多核苷酸，多肽，分离病毒颗粒，病毒颗粒和抗病毒抗体的方法，以及检测方法 提供病毒。 公开了具有核苷酸序列的非B非非C非丙型肝炎病毒基因，其可以通过使用具有所示核苷酸序列的寡核苷酸通过PCR扩增长度为约3500个核苷酸至约4000个核苷酸的序列 或具有SEQ ID NO：60所示的核苷酸序列的寡核苷酸作为引物，或者使用具有SEQ ID NO：57所示核苷酸序列的寡核苷酸的PCR和具有SEQ ID NO： NO：61为引物。 基于该基因的核苷酸序列，提供多肽等。

公开(公告)号：US20040142448A1

公开(公告)日：2004-07-22

申请号：US10302547

申请日：2002-11-21

Inventor： Brian R. Murphy ,  Peter L. Collins ,  Mario H. Skiadopoulos ,  Jason T. Newman

IPC: C12N007/01

CPC classification number: C07K14/005 ,  A61K2039/525 ,  C12N7/00 ,  C12N15/86 ,  C12N2760/18622 ,  C12N2760/18643 ,  C12N2760/18661

Abstract: Recombinant human parainfluenza virus type 1 (HPIV1) compostions, formulations and methods are provided. The recombinant HPIV1 viruses and HPIV1 chimeric and chimeric vector viruses provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic composition s for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV1 genome or antigenome.

Abstract translation: 提供重组人副流感病毒1型（HPIV1）组合物，制剂和方法。 根据本发明提供的重组HPIV1病毒和HPIV1嵌合和嵌合载体病毒在许可哺乳动物受试者，包括人中是感染性和减毒的，并且在免疫原性组合物中可用于引发针对一种或多种PIV的免疫应答 非PIV病原体，或针对PIV和非PIV病原体。 还提供了分离的多核苷酸分子和掺入重组HPIV1基因组或反基因组的载体。

公开(公告)号：US20040126753A1

公开(公告)日：2004-07-01

申请号：US10399478

申请日：2003-04-18

Inventor： Ayae Honda ,  Akira Ishihama

IPC: C12Q001/70 ,  C12N009/22 ,  C12N007/01

CPC classification number: C12N9/127

Abstract: This invention relates to a method for producing virus RNA polymerases of RNA viruses, more specifically, virus RNA polymerases of RNA viruses free of virus genomic RNA. The methods described in this invention includes the procedures for preparation of cDNAs for the genes for the component proteins of RNA polymerase of an RNA virus, incorporation of the cDNA into baculovirus genome to construct recombinant virus, and the infection of insect cells with the recombinant virus to express RNA polymerase. In this method, it is recommended that all species of the recombinant viruses, each of which is designed for expressing each of the above-mentioned component protein genes of RNA polymerase, are coinfected into insect cells. Thus, cDNA is prepared for each of the component proteins of RNA polymerase and incorporated into baculovirus genome to construct recombinant virus for independently expressing the corresponding protein. In addition, the RNA viruses described above include influenza virus especially. In this method, RNA polymerase may be tagged to facilitate the subsequent purification. Furthermore, the tagged RNA polymerase described above may be purified using an adsorbent to trap the RNA polymerase at the tag. Another subject matter of this invention is to artificially prepare a complex of the component proteins of RNA polymerase of an RNA virus, or, in other words, to prepare RNA polymerase free from RNA virus genomic RNA. The RNA viruses described here include influenza virus, and the component proteins of RNA polymerase include PA, PB1 and PB2.

Abstract translation: 本发明涉及一种用于生产RNA病毒的病毒RNA聚合酶的方法，更具体地说，涉及不含病毒基因组RNA的RNA病毒的病毒RNA聚合酶。 本发明描述的方法包括制备用于RNA病毒的RNA聚合酶的组分蛋白的基因的cDNA的方法，将cDNA并入杆状病毒基因组中构建重组病毒，以及用重组病毒感染昆虫细胞 以表达RNA聚合酶。 在该方法中，推荐将所有种类的重组病毒（其各自设计用于表达RNA聚合酶的上述成分蛋白质基因的每一种）共同感染到昆虫细胞中。 因此，为每种RNA聚合酶的组分蛋白制备cDNA，并将其并入杆状病毒基因组中以构建用于独立表达相应蛋白质的重组病毒。 此外，上述RNA病毒特别包括流感病毒。 在该方法中，RNA聚合酶可被标记以促进随后的纯化。 此外，可以使用吸附剂来纯化上述标记的RNA聚合酶，以将RNA聚合酶捕获在标签上。 本发明的另一主题是人造制备RNA病毒的RNA聚合酶的组分蛋白质的复合物，或换句话说，制备不含RNA病毒基因组RNA的RNA聚合酶。 这里描述的RNA病毒包括流感病毒，RNA聚合酶的组分蛋白包括PA，PB1和PB2。

公开(公告)号：US20040120929A1

公开(公告)日：2004-06-24

申请号：US10477375

申请日：2004-02-12

Inventor： Chamsy Sarkis ,  Yi He ,  Che Serguera ,  Noelle Dufour ,  Jacques Mallet

IPC: A61K048/00 ,  C12N007/01 ,  C12N015/867

CPC classification number: C12N7/00 ,  A61K48/00 ,  C07K14/005 ,  C12N15/86 ,  C12N2740/16043 ,  C12N2740/16045 ,  C12N2740/16062 ,  C12N2760/20122

Abstract: The invention relates to a defective lentivirus which is pseudotyped with a lyssavirus envelope of the PV (rabies virus) or MOK type (Mokola virus), for example, and to the use thereof, especially in the preparation of a composition for in vivo transfer of genes in astrocytes and also for the treatment of disorders of the central nervous system.

Abstract translation: 本发明涉及一种用PV（狂犬病病毒）或MOK型（莫考拉病毒）的淋巴病毒包膜进行伪型化的有缺陷的慢病毒及其用途，特别是在制备用于体内转移 星形胶质细胞中的基因，也用于治疗中枢神经系统疾病。

公开(公告)号：US20040116660A1

公开(公告)日：2004-06-17

申请号：US10332413

申请日：2003-09-12

Inventor： Robert Edward Johnston ,  Salim Abdool Karim ,  Lynn Morris ,  Ronald Ivar Swanstrom ,  Carolynn Williamson

IPC: C12Q001/70 ,  C12N007/00 ,  C12N015/00 ,  C12N015/63 ,  C07H021/04 ,  C12N015/09 ,  C12N015/74 ,  C07K014/00 ,  C07K017/00 ,  C07K001/00 ,  C12N015/70 ,  C12N007/01

CPC classification number: C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  C12N7/00 ,  C12N2740/16034 ,  C12N2740/16051 ,  C12N2740/16122 ,  C12N2740/16222

Abstract: The invention provides a process for the selection of HIV-1 subtype (clade) C isolates, selected HIV-1 subtype C isolates, their genes and modifications and derivatives thereof for use in prophylactic and therapeutic vaccines to produce proteins and polypeptides for the purpose of eliciting protection against HIV infection or disease. The process for the selection of HIV subtype isolates comprises the steps of isolating viruses from recently infected subjects; generating a consensus sequence for at least part of at least one HIV gene by identifying the most common codon or amino acid among the isolated viruses; and selecting the isolated virus or viruses with a high sequence identity to the consensus sequence. HIV-1 subtype C isolates, designated Du422, Du 151 and Du 179 (assigned Accession Numbers 01032114, 00072724 and 00072725, respectively, by the European Collection of Cell Cultures) are also provided.

Abstract translation: 本发明提供了选择HIV-1亚型（进化枝）C分离物，所选择的HIV-1亚型C分离株，其基因及其修饰和衍生物用于预防和治疗疫苗以产生用于产生蛋白质和多肽的目的的进程 引起艾滋病毒感染或疾病的保护。 选择HIV亚型分离物的过程包括从最近感染的受试者中分离病毒的步骤; 通过鉴定分离的病毒中最常见的密码子或氨基酸，产生至少一部分HIV基因的共有序列; 并选择与共有序列具有高序列同一性的分离的病毒或病毒。 还提供了称为Du422，Du 151和Du 179（分别由欧洲细胞培养物集合分配的登录号01032114，00072724和00072725）的HIV-1亚型C分离物。

公开(公告)号：US20040058439A1

公开(公告)日：2004-03-25

申请号：US10252182

申请日：2002-09-23

Inventor： Kyu-Kye Hwang

IPC: A61K039/12 ,  C12N007/00 ,  C12N007/01 ,  C12N007/02 ,  C12N015/00 ,  C12N015/09 ,  C12N015/63 ,  C12N015/70 ,  C12N015/74 ,  C12N005/00 ,  C12N005/02

CPC classification number: C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2750/14122 ,  C12N2750/14143 ,  C12N2750/14151

Abstract: The invention includes methods and compositions for the production of high titer recombinant adeno-associated virus (rAAV). The disclosed rAAV are useful in gene therapy applications. Methods are based on the use of recombinant herpes virus vectors and result in highly efficient production of rAAV.

Abstract translation: 本发明包括用于生产高滴度重组腺相关病毒（rAAV）的方法和组合物。 所公开的rAAV在基因治疗应用中是有用的。 方法是基于使用重组疱疹病毒载体，并导致rAAV的高效生产。

公开(公告)号：US20040005711A1

公开(公告)日：2004-01-08

申请号：US10406818

申请日：2003-04-04

Inventor： Djoeke Geesje Regts ,  Marijke Holtrop ,  Jan Christiaan Wilschut ,  Catharina Arnoldine H. H. Daemen

IPC: C12N015/86 ,  C12N007/01

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K48/00 ,  A61K2039/585 ,  C12N15/86 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2840/105 ,  C12N2840/60

Abstract: An alphavirus vector system comprising nucleic acid of a human papilloma virus origin is disclosed. A method of treating or preventing cervical cancer is also disclosed. The method includes administering the alphavirus vector system and/or a cell comprising nucleic acid derived from human papilloma virus (HPV) to a subject. The alphavirus vector system or the cell may be administered as a vaccine.

Abstract translation: 公开了包含人乳头瘤病毒起源的核酸的甲病毒载体系统。 还公开了治疗或预防子宫颈癌的方法。 该方法包括向受试者施用甲病毒载体系统和/或包含衍生自人乳头瘤病毒（HPV）的核酸的细胞）。 甲病毒载体系统或细胞可以作为疫苗施用。

公开(公告)号：US20030211597A1

公开(公告)日：2003-11-13

申请号：US10128578

申请日：2002-04-24

Inventor： Fons Bosman ,  Erik Depla ,  Geert Deschamps ,  Erwin Sablon ,  Isabelle Samson ,  Annie Van Broekhoven ,  Joost Haelewyn

IPC: C12Q001/70 ,  C07H021/04 ,  C12N007/01 ,  C12N007/02 ,  A61K038/04 ,  A61K039/29 ,  C07K005/00 ,  C07K007/00 ,  C07K016/00 ,  C07K017/00 ,  C12N015/63 ,  C12N015/09 ,  C12N015/74

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/5258 ,  C07K2319/02 ,  C07K2319/50 ,  C12N7/00 ,  C12N2770/24222 ,  C12N2770/24223

Abstract: The present invention relates to the general field of recombinant protein expression, purification of recombinant proteins, diagnosis of HCV infection, prophylactic treatment against HCV infection and to the prognosing/monitoring of the clinical efficiency of treatment of an individual with chronic hepatitis, or the prognosing/monitoring of the natural disease. In particular, the present invention relates to the use of yeast, i.e. Hansenula or Saccharomyces glycosylation minus strains, for the efficient expression of HCV envelope proteins that are core-glycosylated, purification methods for these proteins, and the use in various applications, such as the use in diagnosis, prophylaxis or therapy of HCV envelope proteins purified according to the present invention,

Abstract translation: 本发明涉及重组蛋白表达的一般领域，重组蛋白的纯化，HCV感染的诊断，HCV感染的预防性治疗以及慢性肝炎个体治疗的临床效果的预测/监测，或预后 /监测自然病。 特别地，本发明涉及酵母，即汉逊酵母或酵母糖基化减去菌株，用于有效表达核糖糖基化的HCV包膜蛋白，这些蛋白质的纯化方法，以及在各种应用中的用途，例如 用于诊断，预防或治疗根据本发明纯化的HCV包膜蛋白，